Moderna Stock Price, News & Analysis

Moderna, Inc. (NASDAQ:MRNA) announced the immediate departure of its Chief Financial Officer, Jorge Gomez, amidst an ongoing internal investigation at his previous employer, Dentsply Sirona Inc. In light of this, David Meline, the recently retired CFO, will resume his role as CFO while the company searches for a new candidate. Moderna emphasizes that these changes come with risks and uncertainties, and encourages stakeholders to refer to its latest filings for detailed risk factors.

Moderna (NASDAQ:MRNA) will host its in-person Science and Technology Day for analysts and investors on May 17, 2022, at 9:00 a.m. ET in Boston, MA. Key presentations will be made by President Stephen Hoge, Chief Scientific Officer Melissa Moore, and other scientists highlighting advances in mRNA technology.

A live webcast will be available on Moderna's investor website, with a replay accessible for one year. Moderna has transformed significantly over the past decade, developing a diverse portfolio of vaccines and therapeutics, particularly noted for its effective COVID-19 vaccine.

Moderna reported strong Q1 2022 results, achieving revenues of $6.1 billion and a net income of $3.7 billion, resulting in a diluted EPS of $8.58. The company reaffirmed its 2022 advance purchase agreements totaling $21 billion and outlined plans for four Phase 3 programs in the second quarter, including COVID booster and flu vaccines. Moderna's pipeline now has 46 programs with 29 in clinical trials, showing robust progress in both preventive and therapeutic mRNA applications.

Moderna (NASDAQ: MRNA) has submitted a variation for conditional marketing authorization to the European Medicines Agency (EMA) for its COVID-19 vaccine, Spikevax, targeting children six months to under six years. This follows the EMA's positive recommendation for use in children aged six years and older. Positive interim results indicated strong antibody responses and a favorable safety profile from the Phase 2/3 KidCOVE study. Efficacy estimates for the younger age group showed 51% effectiveness against Omicron. The company also continues to explore booster doses for pediatric populations.

Moderna plans to establish a state-of-the-art mRNA vaccine manufacturing facility in Quebec, with an annual production capacity of up to 100 million doses. This facility is part of a ten-year strategic partnership with the Government of Canada aimed at enhancing pandemic preparedness. Following the expected certification by Health Canada, the facility will produce vaccines for respiratory viruses, including COVID-19. Construction is set to begin in 2022, with operations anticipated by 2024, creating hundreds of jobs and bolstering Canada's life sciences ecosystem.

Moderna, Inc. (NASDAQ: MRNA) has submitted a request for emergency use authorization (EUA) of its COVID-19 vaccine, mRNA-1273, for children aged 6 months to under 6 years. This submission is based on positive results from the Phase 2/3 KidCOVE study, which showed a robust antibody response and favorable safety profile. Vaccine efficacy was reported at 51% for the 6 months to < 2 years age group and 37% for the 2 years to < 6 years group, similar to adult efficacy. The EUA submission will be finalized next week as Moderna continues to research booster doses for pediatric cohorts.

Moderna has appointed Arpa Garay as the new Chief Commercial Officer, effective May 31, 2022. Ms. Garay brings over 16 years of experience from Merck & Co., where she was Chief Marketing Officer and led significant global marketing strategies. Her extensive background in oncology and digital marketing is expected to bolster Moderna's commercial efforts in mRNA therapeutics. Moderna emphasizes its commitment to innovative therapies, aiming to leverage Ms. Garay's expertise to enhance patient outcomes worldwide.

Moderna's bivalent booster candidate mRNA-1273.211 shows enhanced neutralizing titers against COVID-19 variants, including Omicron. This candidate demonstrated superiority for six months after administration against variants of concern. The tolerability and safety were consistent with the authorized mRNA-1273 booster. Additionally, Moderna is assessing another bivalent booster, mRNA-1273.214, in a Phase 2/3 study, with data expected in Q2 2022. These findings support Moderna's strategy to address ongoing virus mutations and enhance vaccine effectiveness.

Moderna (NASDAQ:MRNA) will host a live conference call on May 4, 2022, at 8:00 a.m. ET to discuss its Q1 2022 financial results and provide a corporate update. Investors can join the call by dialing 866-922-5185 (domestic) or 409-937-8950 (international) with conference ID 2083116. Additionally, a webcast will be available under the Investors section of Moderna's website. Over its decade of existence, Moderna has developed a diverse portfolio of mRNA-based therapeutics and vaccines, including significant contributions to the COVID-19 pandemic response.